Soligenix

Soligenix Net Tangible Assets

The Net Tangible Assets of Soligenix (SNGX) as of Oct 16, 2026 is 5.29 M USD. In the previous year, Net Tangible Assets was 4.12 M USD — a change of 28.51% (higher).

Net Tangible Assets

5.29 MUSD

YoY

28.51%

Last updated:

Net Tangible Assets of Soligenix is 2025 5.29 M USD. Net Tangible Assets of Soligenix was 2024 4.12 M USD. It decreases by 28.51% higher compared to the previous year.

The Soligenix Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
6.23 M USD
Jan 1, 2019
1.44 M USD
Jan 1, 2020
3.74 M USD
Jan 1, 2021
10.72 M USD
Jan 1, 2022
-2.47 M USD
Jan 1, 2023
2.52 M USD
Jan 1, 2024
4.12 M USD
Jan 1, 2025
5.29 M USD
The Soligenix Net Tangible Assets history
YEARNet Tangible AssetsYoY
5.29 MUSD+28.51%
4.12 MUSD+63.26%
2.52 MUSD-202.09%
-2.47 MUSD-123.04%
10.72 MUSD+186.56%
3.74 MUSD+160.37%
1.44 MUSD-76.93%
6.23 MUSD-0.31%
6.25 MUSD-14.00%
7.27 MUSD-3,588.69%
-208,309.00USD-63.06%
-563,889.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Net Tangible Assets of Soligenix is 5.29 M USD in 2025.

Net Tangible Assets of Soligenix changed from 4.12 M USD to 5.29 M USD, representing a 28.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Soligenix since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Soligenix

All Key Metrics — Soligenix